Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Adagene reported 29% overall response rate for muzastotug (ADG126) in MSS colorectal cancer patients at the 20 mg/kg dose, with median overall survival of 19.4 months at 10 mg/kg dose. The company demonstrated improved tolerability with 4% discontinuation rate and no Grade 4-5 adverse events across 67 patients. With $74.5 million in cash as of December 31, 2025, Adagene expects runway into early 2028 and plans to initiate a registration trial once optimal dose is established.

04/01/2026, 5:00 PM • GlobeNewswire

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Adagene has signed a licensing agreement with Third Arc Bio to utilize its SAFEbody technology platform for developing two masked CD3 T cell engagers targeting unique tumor-associated antigens. The deal includes an upfront payment of $5 million and potential milestone payments up to $840 million.

11/13/2025, 7:00 AM • GlobeNewswire

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.

10/31/2025, 7:00 AM • GlobeNewswire

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Adagene will present results of ADG126, a masked anti-CTLA-4 therapy, at the Chinese Society of Clinical Oncology meeting, showcasing promising outcomes in treating microsatellite stable colorectal cancer with an objective response rate of ~30%.

09/05/2025, 9:55 AM • GlobeNewswire

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Adagene received FDA feedback on its clinical development plan for muzastotug (ADG126), an anti-CTLA-4 therapy for microsatellite stable colorectal cancer, with plans to begin Phase 2 patient enrollment in 2H 2025.

07/15/2025, 7:00 AM • GlobeNewswire

Adagene announces up to $25 million strategic investment from Sanofi

Sanofi will invest up to $25 million in Adagene, exercise an option on a third SAFEbody discovery program, and sponsor a combination clinical trial for muzastotug in advanced solid tumors. The investment is expected to extend Adagene's cash runway into 2027.

07/01/2025, 7:00 AM • GlobeNewswire